Gilead Sciences Inc. said on Friday the U.S. Food and Drug Administration had greenlighted expanded use of Trodelvy to treat the most common type of breast cancer, marking the third approval for the drug.
https://www.pharmalive.com/wp-content/uploads/2020/04/Gilead-says-remdesivir-shows-improvement-in-COVID-19-patients-when-used-early-REUTERS-4-29-20.jpeg7331100Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-02-03 10:50:082023-02-03 11:47:36Gilead’s breast cancer drug secures U.S. FDA approval for expanded use
